Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 18,03€ (+363,50%). La mediana è 18,03€ (+363,50%).
| Acquista |
2 |
| Mantieni |
5 |
| Vendi |
1 |
Notizie Vai al feed delle notizie
Curevac closure threatens hundreds of job losses in Tübingen
After the announcement to close the Curevac site, hundreds of employees face deep cuts; the works council expects about two-thirds of jobs to disappear by the end of 2026 and says operational activity is to be stopped on December 31. A taskforce appointed by the state government aims to secure infrastructure and know-how and to offer staff prospects, while Biontech emphasizes a socially acceptable reduction of personnel and support programs. The works council criticizes the management’s limited willingness to negotiate and points out that there are hardly any comparable jobs in the region for highly specialized professionals. » Altro su finanzen.net
Curevac founder accuses Biontech of deception after announced factory closures
Ingmar Hoerr sharply criticizes Biontech and calls the takeover of Curevac a "dumb sale", saying that, according to him, jobs are to be cut and production sites in Marburg, Idar‑Oberstein, Singapore and Tübingen are to be closed. He accuses Biontech of using the takeover primarily to acquire patents and to eliminate a competitor. Hoerr warns that knowledge built up over decades will be lost and at the same time criticizes Biontech's share buyback program as contradictory to the stated reasons for cost cutting. » Altro su welt.de
Curevac founder accuses Biontech of deception after announced site closures
After the takeover of Curevac, founder Ingmar Hoerr accuses Biontech of deception after Biontech announced the closure of several sites, including Tübingen. Around 820 former Curevac employees are affected; up to 1,860 positions could be cut across the group. Biontech justifies the measures with overcapacity and cost reductions, while the union and Tübingen’s mayor sharply criticize and speculate about patent strategies and the prioritization of financial interests. » Altro su faz.net
Dati finanziari dell'azienda
| (EUR) | nov 2025 | |
|---|---|---|
| Ricavi | 54,13M | - |
| Utile lordo | 53,76M | - |
| Utile netto | 273,23M | - |
| EBITDA | 317,86M | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 900,72M€ |
Numero di azioni | 225,17M |
Massimo/minimo a 52 settimane | 4,91€ - 2,12€ |
| Dividendi | No |
Beta | 1,84 |
Rapporto P/E | 5,55 |
Rapporto PEG | 0,40 |
Rapporto P/B | 1,03 |
Rapporto P/S | 16,00 |
Profilo aziendale
CureVac N.V., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung verschiedener transformativer Arzneimittel auf der Basis von Boten-Ribonukleinsäure (mRNA). Es entwickelt prophylaktische Impfstoffe wie die mRNA-basierten Impfstoffkandidaten CV2CoV, der sich in der klinischen Phase 1 gegen SARS-CoV-2 befindet, CV7202, ein prophylaktischer mRNA-basierter Impfstoff, der die klinische Phase 1 gegen Tollwutvirus-Glykoprotein abgeschlossen hat, und CVSQIV, der sich in der klinischen Phase 1 gegen Influenza befindet, sowie Impfstoffe gegen Lassa-Fieber, Gelbfieber, Respiratorisches Synzytialvirus, Rotavirus, Malaria und universelle Grippe. Das Unternehmen entwickelt auch RNA-basierte Krebsimmuntherapien, darunter CV8102, das sich in der klinischen Phase 1 zur Behandlung von kutanem Melanom und adenoid-zystischem Karzinom sowie Plattenepithelkarzinomen der Haut, des Kopfes und des Halses befindet. Das Unternehmen wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Tübingen, Deutschland.
| Nome | CureVac |
| CEO | Alexander Zehnder |
| Sede centrale | Tübingen,
Paesi Bassi |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 14/08/2020 |
| Dipendenti | 825 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | CVAC |
XETRA | 5CV.F |
XETRA | 5CV.DE |
Frankfurt | 5CV.F |
Düsseldorf | 5CV.DU |
Hamburg | 5CV.HM |
Milan | 1CVAC.MI |
London | 0A9E.L |
SIX | 5CV.SW |
München | 5CV.MU |
Wien | CVAC.VI |
Scopri gli asset
Gli azionisti di CureVac investono anche nei seguenti asset
